04:22 AM EDT, 10/16/2026 (MT Newswires) -- PolyPeptide Group (PPGN.SW) suitor Samsung Biologics held 29,123,892 shares, or 87.92% of the company's total issued share capital and voting rights, at the close of the main offer period for the Swiss contract manufacturer. The South Korean contract development and manufacturing organization is making the offer through its direct subsidiary Samsung Peptide. A total of 29,014,418 PolyPeptide shares were tendered by the Oct. 12 deadline, representing 87.88% of the shares covered by the offer. An additional acceptance period will open on Oct. 19, 2026, and will run through Oct. 30, 2026. Settlement is expected by Nov. 13, 2026, with the entire transaction anticipated to be completed near the end of 2026 or in the first quarter of 2027.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.